Cargando…
Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
The forward (k(on)) and reverse (k(off)) rate constants of drug–target interactions have important implications for therapeutic efficacy. Hence, time-resolved assays capable of measuring these binding rate constants may be informative to drug discovery efforts. Here, we used an ion channel activatio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071183/ https://www.ncbi.nlm.nih.gov/pubmed/33920848 http://dx.doi.org/10.3390/ijms22084078 |
_version_ | 1783683641218433024 |
---|---|
author | Ågren, Richard Stepniewski, Tomasz Maciej Zeberg, Hugo Selent, Jana Sahlholm, Kristoffer |
author_facet | Ågren, Richard Stepniewski, Tomasz Maciej Zeberg, Hugo Selent, Jana Sahlholm, Kristoffer |
author_sort | Ågren, Richard |
collection | PubMed |
description | The forward (k(on)) and reverse (k(off)) rate constants of drug–target interactions have important implications for therapeutic efficacy. Hence, time-resolved assays capable of measuring these binding rate constants may be informative to drug discovery efforts. Here, we used an ion channel activation assay to estimate the k(on)s and k(off)s of four dopamine D(2) receptor (D(2)R) agonists; dopamine (DA), p-tyramine, (R)- and (S)-5-OH-dipropylaminotetralin (DPAT). We further probed the role of the conserved serine S193(5.42) by mutagenesis, taking advantage of the preferential interaction of (S)-, but not (R)-5-OH-DPAT with this residue. Results suggested similar k(off)s for the two 5-OH-DPAT enantiomers at wild-type (WT) D(2)R, both being slower than the k(off)s of DA and p-tyramine. Conversely, the k(on) of (S)-5-OH-DPAT was estimated to be higher than that of (R)-5-OH-DPAT, in agreement with the higher potency of the (S)-enantiomer. Furthermore, S193(5.42)A mutation lowered the k(on) of (S)-5-OH-DPAT and reduced the potency difference between the two 5-OH-DPAT enantiomers. Kinetic K(d)s derived from the k(off) and k(on) estimates correlated well with EC(50) values for all four compounds across four orders of magnitude, strengthening the notion that our assay captured meaningful information about binding kinetics. The approach presented here may thus prove valuable for characterizing D(2)R agonist candidate drugs. |
format | Online Article Text |
id | pubmed-8071183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80711832021-04-26 Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue Ågren, Richard Stepniewski, Tomasz Maciej Zeberg, Hugo Selent, Jana Sahlholm, Kristoffer Int J Mol Sci Article The forward (k(on)) and reverse (k(off)) rate constants of drug–target interactions have important implications for therapeutic efficacy. Hence, time-resolved assays capable of measuring these binding rate constants may be informative to drug discovery efforts. Here, we used an ion channel activation assay to estimate the k(on)s and k(off)s of four dopamine D(2) receptor (D(2)R) agonists; dopamine (DA), p-tyramine, (R)- and (S)-5-OH-dipropylaminotetralin (DPAT). We further probed the role of the conserved serine S193(5.42) by mutagenesis, taking advantage of the preferential interaction of (S)-, but not (R)-5-OH-DPAT with this residue. Results suggested similar k(off)s for the two 5-OH-DPAT enantiomers at wild-type (WT) D(2)R, both being slower than the k(off)s of DA and p-tyramine. Conversely, the k(on) of (S)-5-OH-DPAT was estimated to be higher than that of (R)-5-OH-DPAT, in agreement with the higher potency of the (S)-enantiomer. Furthermore, S193(5.42)A mutation lowered the k(on) of (S)-5-OH-DPAT and reduced the potency difference between the two 5-OH-DPAT enantiomers. Kinetic K(d)s derived from the k(off) and k(on) estimates correlated well with EC(50) values for all four compounds across four orders of magnitude, strengthening the notion that our assay captured meaningful information about binding kinetics. The approach presented here may thus prove valuable for characterizing D(2)R agonist candidate drugs. MDPI 2021-04-15 /pmc/articles/PMC8071183/ /pubmed/33920848 http://dx.doi.org/10.3390/ijms22084078 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ågren, Richard Stepniewski, Tomasz Maciej Zeberg, Hugo Selent, Jana Sahlholm, Kristoffer Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue |
title | Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue |
title_full | Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue |
title_fullStr | Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue |
title_full_unstemmed | Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue |
title_short | Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue |
title_sort | dopamine d(2) receptor agonist binding kinetics—role of a conserved serine residue |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071183/ https://www.ncbi.nlm.nih.gov/pubmed/33920848 http://dx.doi.org/10.3390/ijms22084078 |
work_keys_str_mv | AT agrenrichard dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue AT stepniewskitomaszmaciej dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue AT zeberghugo dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue AT selentjana dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue AT sahlholmkristoffer dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue |